Healthcare Industry News: Mobetron
News Release - January 16, 2008
Groundbreaking Medical Device Helps Woman Win Battle Against CancerIntraOp's Mobetron helps save Ohio woman diagnosed with recurrent liposarcoma
SUNNYVALE, Calif.--(HSMN NewsFeed)--IntraOp Medical Corporation (OTCBB: IOPM ), a provider of innovative technology solutions for the treatment and eradication of cancer, has reported that the Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute (The James) in Columbus, Ohio, has successfully treated a liposarcoma patient using the innovative cancer-fighting device, the Mobetron. The Mobetron administers intraoperative electron-beam radiation therapy (IOERT) at the time of cancer surgery.
In the Fall of 2000, Diane Miesse, a buyer for the U.S. Military living in Columbus Ohio, began to experience back pain. After no relief with conservative pain management, her doctor ordered a CAT scan. The results surprised the medical team. Diane was diagnosed with liposarcoma, a malignant tumor that arises in fat cells found in deep, soft tissue. After several rounds of treatment and recurrences, Diane was referred to The James to work with Dr. Michael Walter, a surgical oncologist, and Dr. John C. Grecula, a radiation oncologist. The doctors treated Diane using the Mobetron during the surgery to administer the IOERT treatment to target any remaining cancer cells in the area.
The Mobetron is the first OR-ready, fully portable, self-shielding electron-beam linear accelerator designed for use in any operating room. With the Mobetron, radiation and surgical oncologists can pinpoint the exact area that requires radiation and immediately deliver high doses directly to the affected tissue during cancer surgery. Hospitals can wheel the Mobetron between existing operating rooms without investing in costly renovations to accommodate traditional radiation therapy devices. Key benefits of the Mobetron include: better local tumor control, shorter treatment cycles, fewer side effects and increased survival rates.
“The Mobetron allows us much more flexibility in the delivery of IOERT. In most cases, the Mobetron can be moved over the patient rather than moving the patient to the linear accelerator. This not only speeds up the delivery process but also increases the safety for the patient. Also the beam collimator (radiation applicator) is aligned to the linear accelerator utilizing a laser system so the sterile environment of the operative field is maintained,” said Dr. Grecula.
Diane commented, "I want to emphasize that prayer and faith played a big part in my recovery, as well as friends, relatives, and my church. I could not have gotten through this without them. I was so thankful that my doctor was aware of IOERT and that I was able to take advantage of the latest technology in cancer treatment."
IntraOp’s Mobetron is available in leading institutions in the United States including University of California San Francisco, University of North Carolina, University Hospital Cleveland, Mayo Clinic Phoenix, Ohio State University, Clarion Methodist Hospital Indianapolis, St. Vincent’s Hospital in Indianapolis, University of Louisville and St. Joseph’s Hospital in Orange, CA.
For more information on Dianne's story please visit http://intraopmedical.com/news/press/20080115_diane_miesse.php.
IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer radiation therapy safely and effectively – for all cancer patients. The company’s flagship product, the Mobetron, is the first fully portable, self-shielding intraoperative electron radiation therapy device designed for use in any operating room. Key Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Leading hospitals, from university research centers to specialized cancer clinics in North America, Europe and Asia, use the Mobetron as a vital part of their comprehensive cancer program.
For more information on IntraOp Medical Corporation, please visit www.intraopmedical.com
Source: IntraOp Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.